



C A R D I O M E

July 26<sup>th</sup>, 2018

**Re: Cardiome Pharma Corp. Announces New Name – Cipher Pharmaceuticals**

Dear Healthcare Professional,

We are excited to announce that the completion of the acquisition of Cardiome Pharma Corp. by Cipher Pharmaceuticals is now complete. Effective August 1, 2018, Cardiome Pharma Corp. will operate as Cipher Pharmaceuticals and will transition all Canadian operations from Vancouver, B.C., to Mississauga, ON.

This is an exciting and important milestone for Cipher.

Publicly traded since 2004, Cipher is a Canadian specialty pharmaceutical company with a robust and diversified portfolio of commercial and late-stage products. Currently promoted products include Epuris<sup>®</sup>, Actikerall<sup>®</sup>, Ozanex<sup>™</sup>, and Vaniqa<sup>®</sup>. The acquisition of Cardiome's Canadian business bolsters Cipher's pipeline and will allow growth into the Hospital Acute Care market. Cipher will assume the marketing, sale and distribution of Cardiome's current brands, including Brinavess<sup>®</sup> (vernakalant hydrochloride) and Aggrastat<sup>®</sup> (tirofiban hydrochloride). In addition, Cipher has acquired dalbavancin hydrochloride, currently under review by Health Canada.

Cipher operates with a high standard of service to our healthcare community and patients and takes pride in delivering innovative and differentiated products that address unmet needs in a range of therapeutic areas, including Cardiology, Infectious Disease and Dermatology.

All further communication about Brinavess<sup>®</sup> and Aggrastat<sup>®</sup> will reflect the new Cipher Pharmaceuticals corporate identity. Product samples and trade packs will transition to the new branding over the course of 2018-2019.

We look forward to continuing to partner with you under the new Cipher name and to deliver on our commitment of high quality service. You should expect to hear from Cipher's team in the coming months. In the meantime, should you have any product-related inquires, please contact us directly at 1-888-361-7207.

Sincerely,

Rob Tessarolo  
Chief Executive Officer  
Cipher Pharmaceuticals  
[www.cipherpharma.com](http://www.cipherpharma.com)